logo
  

H.B. Fuller Profit Misses Estimates; Cuts Guidance Again

Adhesives and sealants maker H.B. Fuller Co (FUL) on Wednesday reported third-quarter net earnings of $26.8 million or $0.52 per share compared with $4 million or $0.08 per share last year.

Excluding items, adjusted earnings for the quarter were $0.61 per share compared with $0.42 per share a year ago.

Revenues for the quarter were slightly down at $524.1 million compared with $526.8 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.70 per share on revenues of $537.2 million for the quarter. Analysts' estimates typically exclude special items.

The company noted that while higher volume positively impacted revenue growth by 6.2 percentage points, foreign currency translation negatively impacted growth by 7.2 percentage points.

Gross margin improved to 28% from 23.8% a year ago.

For the full year 2015, the company again cut its guidance to reflect lower revenue expectation in the Americas operating segment and a slightly higher tax rate.

The company now expects adjusted earnings of $2.23 per share on revenues of about $2.08 billion. Earlier it estimated earnings of $2.45 per share on revenues of $2.1 billion.

Analysts expect earnings of $2.41 per share on revenues of $2.12 billion for 2015.

For the fourth quarter, the company expects adjusted earnings of $0.70 per share on revenues of about $540 million. Analysts expect earnings of $0.80 per share on revenues of $567.6 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT